Effectiveness of intravitreal bevacizumab injection in patients has macular edema due to central retinal vein occlusion

Basit Öğe Kaydı
dc.contributor.authorŞahin M.
dc.contributor.authorYüksel H.
dc.contributor.authorŞahin A.
dc.contributor.authorCingü A.K.
dc.contributor.authorTürkcü F.M.
dc.contributor.authorÇinar Y.
dc.contributor.authorÇaça I.
dc.date.accessioned2024-04-24T18:43:46Z
dc.date.available2024-04-24T18:43:46Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurpose: To evaluate effectiveness of intravitreal bevacizumab injection (IVBI) in patients has with macular edema (ME) due to central retinal vein occlusion (CRVO). Materials and Methods: Between January 2007-May 2012 the patients who treated with IVBI due to ME secondary to CRVO was rewieved retrospectively. Patients demographic characteristics, medical history, complete ophthalmologic examination including visual acuity(VA) before and after IVBI, optical coherence tomography and central macular thickness (CMT), fundus angiography, retinal ischemia were recorded. VA measurements were converted to LogMAR. CRVO was divided into 2 groups as ischemic and nonischemic. Results: 22 (16 male, 6 female) eyes of 22 patients were included. The age of the patients was 60.9±10.5 (39-80) years. Five of the patients were ischemic and 17 of them were nonischemic. The age of ischemic and nonischemic group was 64.6±9.5, 60.4±11 years, respectively (p>0.05). IVBI was applied 3.2±0.8 times in ischemic group and 2.0±1.1 times in nonischemic group. The follow up time was 3.7±2 months (1-6 months). All patients' baseline, 1, 3, 6. month VA were 1.28±0.71, 0.92±0.55, 0.93±0.35 and 0.70±0.49 LogMAR respectively. Although not significant, final VA was increased according to first VA. The CMT measurement of patients was 630±169 ?m in baseline, in 1. month it was 395±152 ?m, at 3.month they were 465±243 ?m, at 6. month they were 395±98 ?m level and there was statistically significant decrease according to the baseline record, 1, 3 and 6. month. Conclusion: Although IVBI is an effective treatment for ME due to CRVO there was an increase in VA in short term, the main limitations are being effective in short term and needing repeated injections. © 2015 Hematolojik Hastaliklarda Góz Bulgulari.en_US
dc.identifier.endpage131en_US
dc.identifier.issn1300-1256
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-84942852172en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage127en_US
dc.identifier.urihttps://hdl.handle.net/11468/24367
dc.identifier.volume22en_US
dc.indekslendigikaynakScopus
dc.language.isotren_US
dc.publisherGazi Eye Foundationen_US
dc.relation.ispartofRetina-Vitreusen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCentral Retinal Vein Occlusionen_US
dc.subjectIntravitreal Bevacizumaben_US
dc.subjectMacular Edemaen_US
dc.titleEffectiveness of intravitreal bevacizumab injection in patients has macular edema due to central retinal vein occlusionen_US
dc.title.alternativeSantral Retinal Ven Tıkanıklı?ına Ba?lı Maküla Ödeminde ?ntravitreal Bevacizumab Enjeksiyonunun Etkinli?ien_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu